Treatment options for anemia in the elderly. (August 2019)

• Record Type: Journal Article
• Authors: Busti, Fabiana; Marchi, Giacomo; Lira Zidanes, Acaynne; Castagna, Annalisa; Girelli, Domenico
• Is Part Of: Transfusion and apheresis science. Volume 58:Number 4(2019)
• Page Start: 416
• Page End: 421
• Publication Date: 2019-08
• Subjects: Anemia -- Elderly -- Aging -- Iron deficiency -- Clonal hematopoiesis -- Hepcidin; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2019.06.018
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Anemia in elderly (AE), though often mild, is quite common and independently associated with important clinical outcomes, including decreased quality of life, risk of falls and fractures, cognitive decline, increased length of hospital stay, and even mortality. AE is generally overlooked, and hence undertreated, especially when comorbidities distract the attention of physicians and caregivers. This also partially reflects difficulties in dissecting the cause(s) of AE, which is typically multifactorial, as well as our limited diagnostic approach often categorizing AE as apparently "unexplained". Therapeutic approaches have been traditionally limited to transfusions, or supplementation with hematinics, including group B vitamins and iron. The latter has been largely underutilized, because of missing diagnosis of iron deficiency using inappropriate laboratory thresholds, as well as complex schedule and adverse effects associated with traditional preparations. After decades of stagnation, new oral and intravenous iron preparations look promising, particularly in the elderly. Moreover, a number of innovative anti-anemic drugs, like hepcidin modulators, Hypoxia Inducible Factor (HIF) stabilizers, and activin type II receptor agonists are entering the clinical arena and may substantially improve our therapeutic armamentarium to AE in the near future.